Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
- 7 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 25 (5), 899-905
- https://doi.org/10.1007/s10147-019-01613-9
Abstract
Prognostic outcomes and safety following treatment with pembrolizumab in patients with advanced urothelial carcinoma (UC) have not been fully elucidated in clinical practice. The aim of this study was to evaluate the oncological efficacy and safety of pembrolizumab after failure of platinum-based chemotherapy in Japanese patients with advanced UC in a routine clinical setting.Keywords
This publication has 30 references indexed in Scilit:
- Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder CancerDisease Markers, 2016
- Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell CarcinomaCancer Immunology Research, 2016
- Molecular biology and targeted therapies for urothelial carcinomaCancer Treatment Reviews, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Cancer-related inflammation and treatment effectivenessThe Lancet Oncology, 2014
- The Predictive Value of C-reactive Protein for Prognosis in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Multi-institutional StudyEuropean Urology, 2014
- Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 TrialsEuropean Urology, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing RegimensJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009